Physician profile
Daniela Tangeman
NPI 1225517196
$1,323.51
in general payments reported to CMS, 2019-2025
14 companies · $493 in 2025
The $493 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $65.87 · 2023: $45.16 · 2024: $466 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $426.51 | 2024-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $344.56 | 2021-2025 | Wainua, Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $179.37 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $102.56 | 2022-2025 | |
| Amgen INC. | $45.66 | 2025 | Repatha |
| Pfizer INC. | $42.51 | 2025 | |
| Novo Nordisk INC | $36.05 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Baxter Healthcare | $31.80 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $26.98 | 2025 | |
| Philips North America LLC | $20.38 | 2024 | (Ck4) Mcot |
| Kestra Medical Technology Services, INC. | $19.69 | 2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $17.48 | 2023 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $15.97 | 2024 | Uptravi, Opsumit |
| Abiomed | $13.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Tangeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.